spacer
The Healthcare Sales & Marketing Network celebrates 25 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  antipsychotic 

 HSMN NewsFeed - 3 Nov 2022
Emalex Biosciences Announces $250 Million Financing Round to Advance Investigational New Drug for Tourette Syndrome
Biopharmaceuticals Neurology Venture Capital
 HSMN NewsFeed - 25 Jun 2021
Jazz Pharmaceuticals Announces Orphan Drug Exclusivity for Xywav(TM) (calcium, magnesium, potassium, and sodium oxybates) Oral Solution
Biopharmaceuticals FDA
 HSMN NewsFeed - 22 Jul 2020
Jazz Pharmaceuticals Announces U.S. FDA Approval of Xywav(TM) (calcium, magnesium, potassium, and sodium oxybates) Oral Solution for Cataplexy or Excessive Daytime Sleepiness Associated with Narcolepsy
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 26 May 2020
Relmada Therapeutics Appoints Molly Harper as Executive Vice President of Operations
Biopharmaceuticals Personnel
 HSMN NewsFeed - 31 Mar 2020
Relmada Therapeutics Solidifies its R&D Leadership Team with the Appointment of Marc de Somer, MD, MBA, ScD, MPH, MSc, as Senior Vice President, Clinical Development and Safety
Biopharmaceuticals Personnel
 HSMN NewsFeed - 9 Mar 2020
Relmada Therapeutics Appoints CNS Specialist Thomas C. Wessel, M.D., Ph.D., as Executive Vice President, Head of Research and Development
Biopharmaceuticals Neurology Personnel
 HSMN NewsFeed - 14 Jan 2020
ANI Announces Launch of Paliperidone Extended-Release Tablets
Biopharmaceuticals Generics Product Launch
 HSMN NewsFeed - 15 Jul 2019
Alkermes Expands Planned New Drug Application for ALKS 3831 to Include Treatment of Bipolar I Disorder
Biopharmaceuticals FDA
 HSMN NewsFeed - 9 Apr 2019
Alkermes Announces Positive Topline Results From Innovative Study of ARISTADA(R) and INVEGA SUSTENNA(R) for the Treatment of Schizophrenia
Biopharmaceuticals
 HSMN NewsFeed - 28 May 2018
Luye Pharma Acquires AstraZeneca's Signature Products Seroquel and Seroquel XR
Biopharmaceuticals Neurology Acquisitions
 HSMN NewsFeed - 3 Apr 2018
Dr. Ottavio Vitolo Joins Relmada Therapeutics as Senior Vice President, Head of R&D and Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 17 Jan 2018
Relmada Therapeutics Acquires Global Rights to Develop and Market Dextromethadone for Treatment of Disorders of the Nervous System
Biopharmaceuticals Neurology Acquisitions
 HSMN NewsFeed - 21 Nov 2017
Sumitomo Dainippon Pharma and Angelini Announce Partnership for Commercialization of Latuda(R) (Lurasidone Hydrochloride) in Europe
Biopharmaceuticals Licensing Distribution
 HSMN NewsFeed - 13 Nov 2017
Allergan Receives FDA Approval For Use of VRAYLAR(TM) (cariprazine) in the Maintenance Treatment of Schizophrenia
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 5 Oct 2017
Neurocrine Announces FDA Approval of 80 mg INGREZZA(R) (valbenazine) Capsules for the Treatment of Adults with Tardive Dyskinesia (TD)
Biopharmaceuticals Neurology FDA
 HSMN NewsFeed - 7 Aug 2017
Impax Announces Settlement of Contract Litigation on Opana(R) ER (Oxymorphone Hydrochloride) CII Extended-Release Tablets
Biopharmaceuticals Litigation
 HSMN NewsFeed - 21 Apr 2017
Neurocrine Announces INGREZZA(TM) Long-Term Safety and Efficacy Data to be Presented at the 2017 American Academy of Neurology Annual Meeting
Biopharmaceuticals Neurology
 HSMN NewsFeed - 5 Jan 2017
Eisai Acquires All Global Development And Marketing Rights For Chronic Weight Management Treatment Lorcaserin HCI
Biopharmaceuticals Acquisitions
 HSMN NewsFeed - 8 Nov 2016
Orexigen Therapeutics Announces Commercialization and Distributorship Agreement with Valeant for Contrave(R) (naltrexone HCl / bupropion HCl extended release) in Australia and New Zealand
Biopharmaceuticals Distribution
 HSMN NewsFeed - 5 Aug 2016
Allergan and Richter Provide Update on Cariprazine Program
Biopharmaceuticals
 HSMN NewsFeed - 8 Jun 2016
Orexigen Therapeutics Reports Favorable Markman Ruling in Contrave(R) Patent Litigation
Biopharmaceuticals Generics Litigation
 HSMN NewsFeed - 16 Mar 2016
Allergan Announces U.S. Availability of VRAYLAR(TM) (cariprazine) for Treatment of Bipolar Mania and Schizophrenia in Adults
Biopharmaceuticals Product Launch
 HSMN NewsFeed - 13 Mar 2015
Actavis Receives FDA Approval of SAPHRIS(R) for Pediatric Patients (age 10-17) for Acute Treatment of Manic or Mixed Episodes of Bipolar I Disorder
Biopharmaceuticals FDA
 HSMN NewsFeed - 2 Dec 2013
Forest to Acquire U.S. Marketing Rights to Saphris(R) (asenapine) from Merck
Biopharmaceuticals Acquisitions
 HSMN NewsFeed - 29 Nov 2013
New Data Show Efficacy, Safety and Tolerability of Xeplion(R) in Patients with Schizophrenia at Various Stages of the Disease
Biopharmaceuticals
 HSMN NewsFeed - 21 Nov 2013
Otsuka and Lundbeck's Once-Monthly Abilify Maintena(R) (Aripiprazole) Now Approved in Europe for Maintenance Treatment of Schizophrenia in Adult Patients Stabilized with Oral Aripiprazole
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 21 Nov 2013
Forest Laboratories and Gedeon Richter Receive Complete Response Letter for Cariprazine
Biopharmaceuticals FDA
 HSMN NewsFeed - 5 Nov 2013
First and Only FDA-Approved, Non-Hormonal Treatment for Moderate to Severe Hot Flashes Now Available by Prescription in U.S. Pharmacies
Biopharmaceuticals FDA
 HSMN NewsFeed - 30 Jul 2013
Alexza Pharmaceuticals Announces European Launch of ADASUVE(R) (Staccato(R) Loxapine)
Biopharmaceuticals Drug Delivery Product Launch
 HSMN NewsFeed - 7 Jun 2013
Eisai Announces Availability of BELVIQ(R) (lorcaserin HCl) CIV Tablets for Chronic Weight Management in Adults who are Overweight with a Comorbidity or Obese
Biopharmaceuticals
 HSMN NewsFeed - 8 May 2013
Teva and Alexza Announce Teva’s License to Market ADASUVE(R) in the U.S.
Biopharmaceuticals Licensing
 HSMN NewsFeed - 21 Feb 2013
Alexza Receives Marketing Authorization for ADASUVE(R) (Staccato(R) Loxapine) in the European Union
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 18 Dec 2012
Blend Therapeutics Appoints Mark Iwicki as Chief Executive Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 14 Dec 2012
The CHMP Delivers a Positive Opinion Recommending Grant of Marketing Authorization for ADASUVE(R) (Staccato(R) Loxapine) in the European Union
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 25 Jul 2012
NuPathe Appoints Armando Anido as Chief Executive Officer
Biopharmaceuticals Neurology Personnel
 HSMN NewsFeed - 30 May 2012
AssureRx Health Raises $12.5 Million Series C Financing
Diagnostics Personalized Medicine Venture Capital
 HSMN NewsFeed - 28 Feb 2012
Forest Laboratories, Inc. and Gedeon Richter Plc. Announce Results from Two Positive Phase III Trials with the Investigational Antipsychotic Cariprazine for the Treatment of Schizophrenia
Biopharmaceuticals
 HSMN NewsFeed - 8 Feb 2012
Forest Laboratories, Inc. and Gedeon Richter Plc Announce Positive Phase III Results with the Investigational Antipsychotic Cariprazine in Patients with Acute Mania Associated with Bipolar I Disorder
Biopharmaceuticals
 HSMN NewsFeed - 30 Jun 2011
FDA Accepts Submission of New Drug Application for CORLUX for Cushing's Syndrome
Biopharmaceuticals FDA
 HSMN NewsFeed - 9 May 2011
Alkermes to Merge with Elan Drug Technologies to Create Alkermes plc
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 24 Jan 2011
Clinical Data, Inc. Announces FDA Approval of Viibryd(TM) (vilazodone HCl) for Major Depressive Disorder
Biopharmaceuticals FDA
 HSMN NewsFeed - 22 Dec 2010
Corcept Therapeutics Announces Positive Phase 3 Study Results for CORLUX for the Treatment of Cushing's Syndrome
Biopharmaceuticals
 HSMN NewsFeed - 28 Sep 2010
AstraZeneca UK Receives Positive Decision For Seroquel XL(R)[Black Triangle Drug] (Quetiapine Prolonged Release) as an Add-On Treatment of Major Depressive Disorder
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 16 Sep 2010
Steven Lo Joins Corcept as Vice President of Commercial Operations
Biopharmaceuticals Personnel
 HSMN NewsFeed - 15 Jul 2010
Sepracor Inc. to Become Sunovion Pharmaceuticals Inc.
Biopharmaceuticals
 HSMN NewsFeed - 26 May 2010
Staccato(R) Loxapine (AZ-004) Reduced Signs and Symptoms of Agitation as Early as Ten Minutes After Dosing in Patients with Schizophrenia or Bipolar Disorder
Biopharmaceuticals
 HSMN NewsFeed - 11 Jan 2010
Novartis Launches Schizophrenia Treatment Fanapt in the US, Offering Patients an Attractive Alternative to Existing Medications
Biopharmaceuticals
 HSMN NewsFeed - 5 Jan 2010
Corcept Therapeutics Announces Four Anticipated Milestones for 2010
Biopharmaceuticals
 HSMN NewsFeed - 14 Dec 2009
FDA Approves Lilly's ZYPREXA(R) RELPREVV(TM) for Treatment of Schizophrenia in Adults
Biopharmaceuticals FDA
 HSMN NewsFeed - 4 Dec 2009
FDA Approves Lilly's Zyprexa for Two Adolescent Indications
Biopharmaceuticals FDA
 HSMN NewsFeed - 4 Dec 2009
US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder
Biopharmaceuticals FDA
 HSMN NewsFeed - 20 Nov 2009
Pfizer Receives FDA Approval For Geodon(R) (Ziprasidone HCI) Capsules For The Adjunctive Maintenance Treatment Of Bipolar Disorder In Adults
Biopharmaceuticals FDA
 HSMN NewsFeed - 12 Oct 2009
Novartis Enters Into Agreement for Exclusive US and Canadian Rights to Fanapt(TM), an FDA-Approved Oral Therapy for Schizophrenia
Biopharmaceuticals Licensing
 HSMN NewsFeed - 12 Oct 2009
Vanda Pharmaceuticals Enters into an Exclusive License Agreement for the Commercialization and Development of Fanapt(TM) in the U.S. and Canada for the Treatment of Schizophrenia
Biopharmaceuticals Licensing
 HSMN NewsFeed - 25 Sep 2009
Teva Provides Update on Generic Seroquel(R) Litigation
Biopharmaceuticals Generics Litigation
 HSMN NewsFeed - 14 Sep 2009
Schering-Plough Reports Data From SAPHRIS(R) (asenapine) Long-Term Schizophrenia Relapse Prevention Study
Biopharmaceuticals
 HSMN NewsFeed - 1 Sep 2009
ACADIA Pharmaceuticals Announces Results from Phase III Trial of Pimavanserin in Parkinson's Disease Psychosis
Biopharmaceuticals Neurology
 HSMN NewsFeed - 24 Jul 2009
SAPHRIS(R) (asenapine) Meets Primary Endpoint in Long-Term Extension Study in Patients With Predominant, Persistent Negative Symptoms of Schizophrenia
Biopharmaceuticals
 HSMN NewsFeed - 20 Jul 2009
Mylan Receives FDA Approval for Additional Strengths of the Antipsychotic Haloperidol
Biopharmaceuticals FDA
 HSMN NewsFeed - 18 May 2009
FDA Grants Approval for Use of RISPERDAL(R) CONSTA(R) as Both a Monotherapy and Adjunctive Therapy in the Maintenance Treatment of Bipolar I Disorder
Biopharmaceuticals FDA
 HSMN NewsFeed - 27 Apr 2009
RISPERDAL CONSTA Approved in Japan
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 23 Mar 2009
FDA Approves Symbyax(R) as First Medication for Treatment-Resistant Depression
Biopharmaceuticals FDA
 HSMN NewsFeed - 9 Mar 2009
Merck and Schering-Plough to Merge
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 23 Feb 2009
AstraZeneca Announces SEROQUEL XR is Now Available to Treat Bipolar Depression
Biopharmaceuticals
 HSMN NewsFeed - 20 Feb 2009
Schering-Plough Submits Response to FDA for SAPHRIS(TM) (asenapine) in the Acute Treatment of Both Schizophrenia and Bipolar I Disorder
Biopharmaceuticals
 HSMN NewsFeed - 12 Feb 2009
Otsuka America Pharmaceutical, Inc. Announces the Appointment of Mark Altmeyer as President and Chief Executive Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 10 Feb 2009
FDA Issues Complete Response Letter for RISPERDAL(R) CONSTA(R) for the Adjunctive Maintenance Treatment of Bipolar Disorder
Biopharmaceuticals FDA
 HSMN NewsFeed - 6 Feb 2009
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Announces FDA Filings for Paliperidone Palmitate and INVEGA(R)
Biopharmaceuticals FDA
 HSMN NewsFeed - 30 Jan 2009
Teva Announces Approval of Generic Risperdal(R) Oral Solution
Biopharmacueticals Generics FDA
 HSMN NewsFeed - 15 Jan 2009
Lilly Resolves Investigations of Past Zyprexa Marketing and Promotional Practices
Biopharmaceuticals
 HSMN NewsFeed - 14 Jan 2009
U.S. FDA Issues Complete Response Letter for SAPHRIS(TM) (ASENAPINE) in the Acute Treatment of Both Schizophrenia and Bipolar I Disorder
Biopharmaceuticals
 HSMN NewsFeed - 5 Dec 2008
Orexigen(R) Therapeutics Announces Changes to Its Clinical Programs and Management Team
Biopharmaceuticals Personnel
 HSMN NewsFeed - 2 Dec 2008
Caroline Loewy Joins Corcept as Chief Financial Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 10 Oct 2008
FDA Approves AstraZeneca's SEROQUEL XR(R) for the Treatment of Bipolar Depression and Bipolar Mania
Biopharmaceuticals FDA
 HSMN NewsFeed - 7 Oct 2008
Eli Lilly and Company Resolves Investigation Involving Numerous States
Biopharmaceuticals
 HSMN NewsFeed - 26 Sep 2008
CHMP Recommends Approval of Olanzapine Long-acting Injection for Maintenance Treatment of Schizophrenia in Europe
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 28 Jul 2008
FDA Issues Not Approvable Letter for Iloperidone to Vanda Pharmaceuticals
Biopharmaceuticals FDA
 HSMN NewsFeed - 28 Jul 2008
Vanda Pharmaceuticals Announces Receipt of Not Approvable Letter From FDA for Iloperidone
Biopharmaceuticals FDA
 HSMN NewsFeed - 14 May 2008
FDA Approves AstraZeneca's Seroquel(R) for Maintenance Treatment in Bipolar Disorder
Biopharmaceuticals FDA
 HSMN NewsFeed - 8 May 2008
AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Generalized Anxiety Disorder - a First for the Atypical Antipsychotic Class of Medicines
Biopharmaceuticals
 HSMN NewsFeed - 7 May 2008
Treatment with Paliperidone ER May Be Associated with Significantly Reduced Use of Mental Health Resources
Biopharmaceuticals
 HSMN NewsFeed - 31 Mar 2008
ACADIA Pharmaceuticals Initiates Second Phase III Trial with Pimavanserin in Patients with Parkinson's Disease Psychosis
Biopharmaceuticals
 HSMN NewsFeed - 24 Mar 2008
Corcept Therapeutics Announces Commencement of Next Phase 3 Study With CORLUX(R) for the Treatment of Psychotic Depression
Biopharmaceuticals
 HSMN NewsFeed - 17 Mar 2008
Corcept Therapeutics Announces $25.3 Million Private Equity Financing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 12 Mar 2008
Statement from Eli Lilly and Company: Response to Connecticut Attorney General News Release
Biopharmaceuticals
 HSMN NewsFeed - 29 Feb 2008
U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for the Acute Treatment of Manic and Mixed Episodes Associated With Bipolar I Disorder in Pediatric Patients (10 to 17 Years of Age)
Biopharmaceuticals FDA
 HSMN NewsFeed - 29 Feb 2008
AstraZeneca Submits sNDA for SEROQUEL XR(TM) for the Treatment of Major Depressive Disorder
Biopharmaceuticals
 HSMN NewsFeed - 29 Feb 2008
Wyeth Pharmaceuticals Ends Collaboration Agreements with Solvay Pharmaceuticals for Bifeprunox and Other Compounds
Biopharmaceuticals
 HSMN NewsFeed - 28 Feb 2008
FDA Issues Not-Approvable Letter for Lilly's Zyprexa(R) Long-Acting Injection (LAI) for Schizophrenia Treatment
Biopharmaceuticals FDA
 HSMN NewsFeed - 25 Feb 2008
Alexza Initiates First Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine)
Biopharmaceuticals
 HSMN NewsFeed - 6 Feb 2008
FDA Advisory Committee Supports Efficacy and Safety of Zyprexa(R) Long-Acting Injection (LAI) for Schizophrenia Treatment
Biopharmaceuticals FDA
 HSMN NewsFeed - 13 Dec 2007
Iloperidone Phase III Clinical Data Demonstrate Efficacy and Favorable Safety and Tolerability Profile
Biopharmaceuticals
 HSMN NewsFeed - 12 Dec 2007
Vanda Presents Phase III Iloperidone Efficacy Data
Biopharmaceuticals
 HSMN NewsFeed - 12 Dec 2007
INVEGA(TM) Shows Favorable Long-Term Safety Profile in a One-Year Study of Patients With Schizophrenia
Biopharmaceuticals
 HSMN NewsFeed - 20 Nov 2007
U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) as the First Medication for Add-On Treatment of Major Depressive Disorder (MDD)
Biopharmaceuticals FDA
 HSMN NewsFeed - 16 Nov 2007
SEROQUEL XR(TM) Receives Approval From FDA for Maintenance Treatment of Schizophrenia
Biopharmaceuticals FDA
 HSMN NewsFeed - 15 Nov 2007
ABILIFY(R) (aripiprazole) Supplemental New Drug Application for the Treatment of Pediatric Patients with Bipolar I Disorder Accepted for Priority Review by the U.S. Food and Drug Administration
Biopharmaceuticals FDA
 HSMN NewsFeed - 14 Nov 2007
Study Shows Organon's Asenapine Demonstrates Efficacy and Tolerability in Treating Acute Schizophrenia
Biopharmaceuticals
 HSMN NewsFeed - 6 Nov 2007
U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for Adolescent Patients With Schizophrenia
Biopharmaceuticals FDA
 HSMN NewsFeed - 29 Oct 2007
Johnson & Johnson Pharmaceutical Research & Development Submits New Drug Application for Paliperidone Palmitate
Biopharmaceuticals FDA
 HSMN NewsFeed - 5 Oct 2007
Lilly Announces Updates to the Zyprexa and Symbyax U.S. Labels
Biopharmaceuticals
 HSMN NewsFeed - 27 Sep 2007
Vanda Pharmaceuticals Submits Iloperidone New Drug Application
Biopharmaceuticals FDA
 HSMN NewsFeed - 11 Sep 2007
Corcept Therapeutics Receives FDA Notification Opening IND for CORLUX(R) for the Treatment of Cushing's Syndrome
Biopharmaceuticals
 HSMN NewsFeed - 7 Sep 2007
Statement of Eli Lilly and Company on Dr. David Egilman Settlement
Biopharmaceuticals Litigation
 HSMN NewsFeed - 22 Aug 2007
FDA Approves RISPERDAL(R) to Treat Adolescents with Schizophrenia and Children and Adolescents with Bipolar Mania
Biopharmaceuticals FDA
 HSMN NewsFeed - 20 Aug 2007
Corcept Therapeutics Announces $10.1 Million Private Equity Financing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 10 Aug 2007
Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
Biopharmaceuticals FDA
 HSMN NewsFeed - 10 Aug 2007
Wyeth Pharmaceuticals and Solvay Pharmaceuticals, Inc. Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
Biopharmaceuticals FDA
 HSMN NewsFeed - 6 Aug 2007
AVANIR Pharmaceuticals Completes Sale Of FazaClo
Biopharmaceuticals Acquisitions
 HSMN NewsFeed - 17 Jul 2007
ABILIFY(R) (aripiprazole) Supplemental New Drug Application Receives Priority Review by U.S. Food And Drug Administration for Adjunctive Treatment in Adults With Major Depressive Disorder
Biopharmaceuticals FDA
 HSMN NewsFeed - 9 Jul 2007
Corcept Therapeutics Receives Orphan Drug Designation for CORLUX(R) Treatment of Cushing's Syndrome
Biopharmaceuticals FDA
 HSMN NewsFeed - 3 Jul 2007
Azur Pharma Announces the Acquisition of FazaClo for $42 Million Plus Contingent Milestones
Biopharmaceuticals Acquisitions
 HSMN NewsFeed - 3 Jul 2007
AVANIR Pharmaceuticals Announces Sale of FazaClo to Fund Continued Development of Zenvia
Biopharmaceuticals
 HSMN NewsFeed - 28 Jun 2007
INVEGA(TM) Receives Marketing Authorization In European Union For Treatment Of Schizophrenia
Biopharmaceuticals Drug Delivery Regulatory
 HSMN NewsFeed - 21 Jun 2007
FDA Issues Approvable Letter for RISPERDAL(R) to Treat Adolescents with Schizophrenia and Children and Adolescents with Bipolar Mania
Biopharmaceuticals FDA
 HSMN NewsFeed - 31 May 2007
AVANIR Receives FDA Approval for New Formulation of Currently Marketed Antipsychotic Drug FazaClo
Biopharmaceuticals FDA
 HSMN NewsFeed - 21 May 2007
Galenea Corp. Appoints Mark Benjamin as Chief Executive Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 18 May 2007
FDA Approves Astrazeneca's Once-Daily Seroquel XR(TM) Extended-Release Tablets for the Treatment of Schizophrenia
Biopharmaceuticals FDA
 HSMN NewsFeed - 27 Apr 2007
FDA Approves INVEGA (TM) for Long-Term Maintenance Treatment of Schizophrenia
Biopharmaceuticals FDA
 HSMN NewsFeed - 25 Apr 2007
Alkermes and Indevus Announce Initiation of Phase 2a Clinical Study of ALKS 27 for the Treatment of COPD
Biopharmaceuticals Drug Delivery
 HSMN NewsFeed - 13 Apr 2007
FDA Approves New Dose of RISPERDAL(R) CONSTA(R) for Schizophrenia Treatment
Biopharmaceuticals FDA
 HSMN NewsFeed - 3 Apr 2007
New Data Show Early Non-Response to Antipsychotic Treatment May Be Strong Predictor of Subsequent Non-Response for People with Schizophrenia
Biopharmaceuticals
 HSMN NewsFeed - 30 Mar 2007
Study Suggests INVEGA(TM) Helps Patients With Schizophrenia Maintain Symptom Control
Biopharmaceuticals
 HSMN NewsFeed - 30 Mar 2007
Safety Analyses of Clinical Data for Bifeprunox in Patients with Schizophrenia Showed a Favorable Weight and Lipid Profile, Similar to Placebo
Biopharmaceuticals
 HSMN NewsFeed - 19 Mar 2007
Corcept Therapeutics Announces Phase 3 Study Evaluating CORLUX(R) for Psychotic Major Depression Misses Primary Endpoint
Biopharmaceuticals
 HSMN NewsFeed - 5 Mar 2007
Alkermes Announces Senior Management Succession Plan
Biopharmaceuticals Personnel
 HSMN NewsFeed - 1 Mar 2007
FDA Grants Pediatric Exclusivity for RISPERDAL(R)
Biopharmaceuticals FDA
 HSMN NewsFeed - 14 Feb 2007
Eli Lilly and Company Statement: Judge Grants Lilly's Request for a Permanent Injunction Involving Misleading Selection of Illegally Leaked Lilly Documents
Biopharmaceuticals Litigation
 HSMN NewsFeed - 30 Jan 2007
AVANIR Receives FDA Approvable Letter for New Formulation of Currently Marketed Antipsychotic Drug FazaClo
Biopharmaceuticals FDA
 HSMN NewsFeed - 11 Jan 2007
Wyeth and Solvay Enter Into an Additional Neuroscience Collaboration
Biopharmaceuticals
 HSMN NewsFeed - 8 Jan 2007
Alkermes and Lilly Expand AIR(R) Inhaled Insulin Collaboration
Biopharmaceuticals Endocrinology Drug Delivery Licensing
 HSMN NewsFeed - 4 Jan 2007
Eli Lilly and Company Statement Regarding Today's New York Times Article - January 4, 2007
Biopharmaceuticals
 HSMN NewsFeed - 4 Jan 2007
Lilly and Plaintiffs' Attorneys Enter Into Agreements to Settle Zyprexa(R) Product Liability Litigation
Biopharmaceuticals Litigation
 HSMN NewsFeed - 4 Jan 2007
Alkermes and Indevus Announce Joint Collaboration to Develop Inhaled Formulation of Trospium Chloride for the Treatment of COPD
Biopharmaceuticals
 HSMN NewsFeed - 27 Dec 2006
Bristol-Myers Squibb and Otsuka Pharmaceutical Co., Ltd. Announce Exclusive Licensing Agreement for Diabetes Compound Saxagliptin in Japan
Biopharmaceuticals Endocrinology Licensing
 HSMN NewsFeed - 20 Dec 2006
Alkermes Announces Submission of New Drug Application for RISPERDAL(R) CONSTA(R) in Japan
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 20 Dec 2006
INVEGA(TM) Approved By FDA as New Treatment for Schizophrenia
Biopharmaceuticals FDA
 HSMN NewsFeed - 14 Dec 2006
CyDex Announces Captisol Technology Used in Recently Launched Injection Formulation of Antipsychotic Medication ABILIFY(R) (aripiprazole)
Biopharmaceuticals Drug Delivery
 HSMN NewsFeed - 12 Dec 2006
ABILIFY(R) (Aripiprazole) Injection for Intramuscular Use for Adults With Agitation Associated With Schizophrenia or Bipolar Mania Now Available
Biopharmaceuticals
 HSMN NewsFeed - 7 Dec 2006
ABILIFY(R) (aripiprazole) Demonstrated Efficacy as Long-Term Maintenance Therapy in Adults With Bipolar I Disorder Following Treatment for a Recent Manic Or Mixed Episode
Biopharmaceuticals
 HSMN NewsFeed - 7 Dec 2006
Vanda Pharmaceuticals Confirms Iloperidone Efficacy With Positive Phase III Clinical Trial Results in Schizophrenia
Biopharmaceuticals
 HSMN NewsFeed - 6 Dec 2006
Bifeprunox Showed Improvement of Symptoms and Maintenance of Stability with Fewer Metabolic Side Effects vs. Placebo in Patients with Schizophrenia
Biopharmaceuticals
 HSMN NewsFeed - 6 Dec 2006
Phase 2 and 3 Clinical Data for Bifeprunox in Patients With Schizophrenia Showed Improvement of Symptoms and Maintenance of Stability With Fewer Metabolic Side Effects Versus Placebo
Biopharmaceuticals
 HSMN NewsFeed - 5 Dec 2006
Cerimon Pharmaceuticals Names Ayse Kocak Vice President of Marketing
Biopharmaceuticals Personnel
 HSMN NewsFeed - 1 Dec 2006
AstraZeneca's Statement on the Cost-Effectiveness Findings of the Clinical Antipsychotic Trials of Intervention Effectiveness-Schizophrenia (CATIE-SZ)
Biopharmaceuticals
 HSMN NewsFeed - 1 Dec 2006
Lilly Responds to the Cost-Effectiveness Analysis of the CATIE Schizophrenia Trial
Biopharmaceuticals
 HSMN NewsFeed - 21 Nov 2006
Celtic Pharma Appoints Two New Senior Executives
Biopharmaceuticals Personnel
 HSMN NewsFeed - 13 Nov 2006
Corcept Therapeutics Completes Enrollment in Third Phase 3 Study for Treating Psychotic Major Depression
Biopharmaceuticals
 HSMN NewsFeed - 10 Nov 2006
Janssen, L.P. Selects INVEGA(TM) (paliperidone) Extended Release tablets as Brand Name for Its Investigational Atypical Antipsychotic
Biopharmaceuticals
 HSMN NewsFeed - 20 Oct 2006
FDA Approves AstraZeneca's SEROQUEL(R) For Bipolar Depression Treatment
Biopharmaceuticals FDA
 HSMN NewsFeed - 13 Oct 2006
Pfizer Names Senior Executive to Head Expanded Worldwide Licensing and Business Development
Biopharmaceuticals Personnel
 HSMN NewsFeed - 6 Oct 2006
FDA Approves RISPERDAL(R) for Treatment of Irritability Associated with Autistic Disorder
Biopharmaceuticals FDA
 HSMN NewsFeed - 29 Sep 2006
Corcept Therapeutics Announces Negative Results From the Second of Three Phase 3 Studies Evaluating CORLUX(R) for Treating the Psychotic Features of Psychotic Major Depression
Biopharmaceuticals
 HSMN NewsFeed - 17 Aug 2006
Bristol-Myers Squibb and Otsuka Pharmaceutical Company Launch New Rapidly Disintegrating Oral Antipsychotic Medication ABILIFY(R) DISCMELT(TM) (aripiprazole)
Biopharmaceuticals Drug Delivery
 HSMN NewsFeed - 18 Jul 2006
AstraZeneca Submits NDA for Sustained Release Formulation of SEROQUEL(R) for Schizophrenia Treatment
Biopharmaceuticals FDA
 HSMN NewsFeed - 12 Jun 2006
Study Demonstrated Once-Weekly Exenatide LAR Improved Glucose Control in Patients with Type 2 Diabetes
Biopharmaceuticals Endocrinology
 HSMN NewsFeed - 5 Jun 2006
Lilly and Alkermes Complete Patient Enrollment for Phase 3 Safety Study for Inhaled Insulin for the Treatment of Diabetes
Biopharmaceuticals Endocrinology Drug Delivery
 HSMN NewsFeed - 25 May 2006
Six-Month Study Evaluated Effectiveness of Aripiprazole and Standard of Care In Management of Community-Treated Patients with Schizophrenia
Biopharmaceuticals
 HSMN NewsFeed - 23 May 2006
Second Investigational Study of SEROQUEL(R) in the Treatment of Depressive Episodes Associated with Bipolar Disorder Confirms Previous Findings
Biopharmaceuticals
 HSMN NewsFeed - 23 May 2006
New Study Suggests Symbyax(R) Significantly Improves Symptoms of Treatment-Resistant Depression
Biopharmaceuticals
 HSMN NewsFeed - 23 May 2006
Clera Announces Senior Management Appointments
Biopharmaceuticals Personnel
 HSMN NewsFeed - 23 May 2006
Clinical Study of Investigational Drug Paliperidone ER Demonstrated Efficacy and Tolerability in the Treatment of Patients With Schizophrenia
Biopharmaceuticals
 HSMN NewsFeed - 23 May 2006
AVANIR Announces the Intended Acquisition of a Private Specialty Pharmaceutical Company
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 22 May 2006
New Studies Examine SEROQUEL(R) in Combination With Antidepressant Therapy in Patients With Depression
Biopharmaceuticals
 HSMN NewsFeed - 22 May 2006
First Head-to-Head Study Suggests Significantly Greater Symptom Improvement for Symbyax(R) Compared to Lamotrigine in Bipolar Depression
Biopharmaceuticals
 HSMN NewsFeed - 22 May 2006
Corcept Therapeutics Completes Enrollment in Second Phase 3 Study for Treating Psychotic Major Depression
Biopharmaceuticals
 HSMN NewsFeed - 16 May 2006
ABILIFY(R) (Aripiprazole) Demonstrated Efficacy as Maintenance Therapy In Adults with Bipolar I Disorder Following Treatment for a Recent Manic or Mixed Episode
Biopharmaceuticals
 HSMN NewsFeed - 1 May 2006
Corcept Therapeutics Completes Enrollment in Phase 3 Study for Treating Psychotic Major Depression
Biopharmaceuticals
 HSMN NewsFeed - 13 Apr 2006
Alkermes and Cephalon Receive FDA Approval of Vivitrol(TM) for the Treatment of Alcohol Dependence
Biopharmaceuticals FDA
 HSMN NewsFeed - 10 Apr 2006
Neuronetics Prepares for Market Launch of New Depression Therapy; Hires Peter Anastasiou as Vice President, Marketing
Devices Neurology Personnel
 HSMN NewsFeed - 30 Mar 2006
CuraGen Appoints Dr. Frank M. Armstrong as Chief Executive Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 24 Mar 2006
New Dosages of RISPERDAL(R) (Risperidone) Now Available
Biopharmaceuticals
 HSMN NewsFeed - 17 Feb 2006
Alkermes Announces Submission of Complete Response to FDA for VIVITROL(TM) New Drug Application
Biopharmaceuticals FDA
 HSMN NewsFeed - 7 Feb 2006
Bristol-Myers Squibb Company and Otsuka Pharmaceutical Co., Ltd. Announce Availability of 2 mg ABILIFY(R) (aripiprazole) Tablet and Nonrefrigerated Oral Solution
Biopharmaceuticals
 HSMN NewsFeed - 9 Jan 2006
Alkermes and Lilly Announce Agreement for the Development and Commercialization of Inhaled Parathyroid Hormone for the Treatment of Osteoporosis
Biopharmaceuticals Drug Delivery
 HSMN NewsFeed - 3 Jan 2006
AstraZeneca Submits sNDA for SEROQUEL(R) for Bipolar Depression Treatment
Biopharmaceuticals FDA
Return to NewsFeed  

 Additional items found! 94

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 94 additional stories matching:
antipsychotic
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.